Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people do not lose noticeable weight in the first two or three weeks on Wegovy, and that is completely normal. Weight loss on semaglutide tends to build gradually over months rather than dropping sharply at the start. The STEP 1 trial, published in the New England Journal of Medicine, recorded an average body-weight reduction of around 15% over 68 weeks — a figure that accumulated steadily, not in the first fortnight. Wegovy is a prescription-only medicine; a prescriber assesses whether it is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misunderstanding our prescribers encounter is that Wegovy should produce rapid, visible results from the very first pen. It does not, and expecting that can lead people to conclude the medicine is not working when it is actually doing exactly what it should.
Here is why. Wegovy's prescribing schedule starts at 0.25mg, a dose chosen purely to ease your body into the medicine. At that level, the appetite-suppressing effect is modest. The therapeutic weight-loss action builds as the dose climbs, typically through 0.5mg, then 1mg, then 1.7mg, before reaching the 2.4mg maintenance dose. That process takes around four months to complete in full, assuming it is well tolerated at each step.
So weeks one to four are mostly about adjustment. Some people notice reduced hunger almost immediately; others feel little change. Both are normal. What tends to happen across the titration period is a slow, compounding reduction in appetite and food intake that translates into weight loss at a pace that is real but not dramatic in any single week. Patients who check the scales daily in week two and see nothing often give up on a medicine that would have worked well for them. How long before weight loss starts on Wegovy is a question worth reading carefully if you are in those early weeks.
Clinical trial data and patient experience broadly agree on a window: weeks four to twelve is when most people on Wegovy begin to see and feel a meaningful change. By week four, many will be on 0.5mg or approaching it. By week twelve, some will have reached 1.7mg. Appetite is noticeably reduced for the majority at this point, and the scale reflects that.
The STEP 1 trial tracked participants weekly and found weight loss accelerating through months two to six, then continuing at a slower rate through to the 68-week endpoint. The first six months carried most of the total reduction. This matters because it reframes what "fast" means: Wegovy is not a short-course treatment. It is a medicine that works progressively, and if you are wondering how quickly you start losing weight on Wegovy, the pace at week three tells you nothing reliable about where you will be at month six.
Individual variation is real. Factors including starting weight, metabolic rate, how consistently you take the injection on the same day each week, and what you eat alongside treatment all influence the curve. Some people lose weight faster early on; others see their biggest results later. For a clearer sense of how long until you start losing weight on Wegovy, it helps to understand that there is no single timeline that applies universally. If you want a practical sense of what influences the pace, strategies for getting the most from Wegovy covers the lifestyle factors the evidence supports.
One practical detail worth mentioning: keeping your pen in the fridge door where you will actually see it makes the weekly injection easier to remember, consistency of dosing affects consistency of effect.
The standard maintenance dose of 2.4mg produces around 15% average weight loss over 68 weeks, per the STEP 1 data. That headline figure has now been joined by evidence from the higher 7.2mg dose, which the MHRA approved in April 2026. Trials at 7.2mg reported average weight loss of around 20.7% over 72 weeks, approaching the results seen with tirzepatide in head-to-head data.
For the timeline question, this changes things modestly: the 7.2mg option adds a further titration step above 2.4mg, meaning the journey to maximum effect is longer still. The result at the end of that longer path is greater, but there is no shortcut through the early weeks. The starting dose remains 0.25mg regardless of which maintenance target you and your prescriber agree on. How quickly Wegovy begins to work mechanically explains the pharmacology if you want to understand what is happening at each step.
Wegovy is available as a prescription-only medicine and requires clinical assessment before treatment. The NHS semaglutide page covers what to expect in plain language. The broader range of weight-loss medicines available through a regulated prescriber is outlined on our weight-loss treatments overview. Pricing and what a private prescription includes are covered separately on our Wegovy treatment page, useful context before you start a consultation. If you are ready to find out whether you are clinically eligible, you can check your eligibility with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.